In this video, we explore the latest breakthroughs in antidepressant augmentation, showing how personalized medicine can enhance outcomes for patients with various forms of depression. Whether your patient is facing anxious depression, depression with insomnia, or psychotic depression, this video offers evidence-based strategies that incorporate augmenation options such as lithium for depression, esketamine for depression, and quetiapine for depression.
Listen to the full text of the issue read aloud by Gregory Malzberg, MD. In this issue, David Jobes shows us how to empower patients while collaboratively assessing suicidality. Eight ways to treat OCD when SSRIs fail. Antipsychotic dosing in mania vs. schizophrenia, and all you need to know about a popular at-home treatment for depression: Transcranial direct stimulation (tDCS).
Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
This video breaks down the findings from a meta-analysis of randomized controlled trials, examining how aripiprazole dosage impacts patient outcomes in clinical depression treatment.
We’re taking a deep dive into Auvelity, a new antidepressant that combines Dextromethorphan and Bupropion. While Bupropion is well-established in the treatment of depression, Dextromethorphan is less familiar in psychiatric contexts.
Research updates on benzo discontinuation, iloperidone in mania, lithium, schizophrenia, ECT, a new circadian psychotherapy, and therapy for multi-trauma PTSD.
0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.